ReviewTurkish journal of ophthalmology2017
Thyroid-associated Ophthalmopathy.
Review in Turkish journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 146 citations in OpenAlex.
- Graves' ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions - a systematic review.BMJ open ophthalmology · 2024Pooled it
- Evaluating and enhancing the performance of large language models in thyroid eye disease through customization and Chain-of-Thought strategies.Scientific reports · 2026Article
- Article
- The floppy thyroid eye disease.International ophthalmology · 2026Article
- How to manage thyroid eye disease: recent advances - a narrative review.Drugs in context · 2026Review
- Positive Relationships between Intraocular Pressure and Thyroid Function in Graves' Ophthalmopathy: A Three-Aspect Evidence Analysis.Yonsei medical journal · 2025Article
- Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study.Endocrine connections · 2025Article
- The miR-320a/PRDX3 Axis Alleviates the Oxidative Stress and Fibrotic Alterations in Fibroblasts in Thyroid Eye Disease.Investigative ophthalmology & visual science · 2025Article
- Three-Dimensional Culture of Orbital Fibroblasts From Thyroid Eye Disease Induce In Vivo-Like Tissue Remodeling and Fibrosis.Investigative ophthalmology & visual science · 2025Article
- Statins and Thyroid Eye Disease: A Propensity Score-Matched Retrospective Cohort Analysis.Cureus · 2025Article
- Combining biomarkers to predict the disease activity of graves' ophthalmopathy: a combinatory model of the NLR, TRAb and FT4.Frontiers in endocrinology · 2025Article
- The burden of illness in thyroid eye disease: current state of the evidence.Frontiers in ophthalmology · 2025Review
- Application of apparent diffusion coefficient of extraocular muscles from diffusion tensor imaging scanning in the assessment of disease activity of thyroid eye disease.BMC endocrine disorders · 2024Article
- Beyond the Thyroid: A Narrative Review of Extra-thyroidal Manifestations in Hashimoto's Disease.Cureus · 2024Review
- Superficial ocular vascular changes after orbital decompression in patients with thyroid ophthalmopathy measured by anterior segment OCT angiography; an observational study.Scientific reports · 2024Observational
- One Incremental Stride for Doxycycline, One Substantial Advancement for Thyroid Eye Disease.Diagnostics (Basel, Switzerland) · 2024Article
- Long-term surgical outcome and impact on daily life activities of strabismus surgery in thyroid-associated ophthalmopathy with and without previous orbital decompression.Head & face medicine · 2024Article
- Serum PD-1 regulation and PD-1 expression of CD4+Foxp3+ regulatory T cells in patients in thyroid eye disease associated with immunosuppression treatment.Frontiers in ophthalmology · 2024Article
- Investigation of Conjunctival Goblet Cell and Tear MUC5AC Protein in Patients With Graves' Ophthalmopathy.Translational vision science & technology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid-associated ophthalmopathy is the most frequent extrathyroidal involvement of Graves' disease but it sometimes occurs in euthyroid or hypothyroid patients. Thyroid-associated ophthalmopathy is an autoimmune disorder, but its pathogenesis is not completely understood. Autoimmunity against putative antigens shared by the thyroid and the orbit plays a role in the pathogenesis of disease. There is an increased volume of extraocular muscles, orbital connective and adipose tissues. Clinical findings of thyroid-associated ophthalmopathy are soft tissue involvement, eyelid retraction, proptosis, compressive optic neuropathy, and restrictive myopathy. To assess the activity of the ophthalmopathy and response to treatment, clinical activity score, which includes manifestations reflecting inflammatory changes, can be used. Supportive approaches can control symptoms and signs in mild cases. In severe active disease, systemic steroid and/or orbital radiotherapy are the main treatments. In inactive disease with proptosis, orbital decompression can be preferred. Miscellaneous treatments such as immunosuppressive drugs, somatostatin analogs, plasmapheresis, intravenous immunoglobulins and anticytokine therapies have been used in patients who are resistant to conventional treatments. Rehabilitative surgeries are often needed after treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.